Oncology

  • 30 January 2020
    News

    EC expands approval of Janssen’s Erleada in prostate cancer

    Janssen Pharmaceutical has received extended approval from the European Commission (EC) for Erleada (apalutamide) combined with androgen deprivation therapy (ADT) to treat adults suffering from metastatic hormone-sensitive prostate cancer (mHSPC).

  • 27 January 2020
    News

    Roche seeks FDA approval for liver cancer treatment

    Roche has filed a supplemental biologics license application (sBLA) with the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) plus Avastin (bevacizumab) to treat unresectable hepatocellular carcinoma (HCC), a...

  • 16 January 2020
    Comment

    Assessing recent approvals in bladder cancer

    On December 18 2019, the FDA granted accelerated approval for Seattle Genetic/Astellas Pharmaceutical’s Padcev (enfortumab vedotin-ejfv). Merck and Co’s Keytruda (pembrolizumab) was granted approval for Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle...

Close
Close
Close

Go Top